title: A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation.
abstract: BACKGROUND
  Bupropion sustained release (bupropion SR) has been shown to increase smoking cessation success rates in the US studies.
  
  
  OBJECTIVE
  To determine whether bupropion SR, in combination with counselling, is effective for smoking cessation in a multi-country study.
  
  
  METHODS
  This randomized, double-blind, placebo-controlled trial enrolled 707 smokers. A total of 527 received bupropion SR 300 mg daily for 7 weeks and 180 received placebo. A total of 11 clinic visits and 10 telephone contacts were scheduled, during the course of 1 year. Seven-week and 12-month abstinence rates were the study outcomes.
  
  
  RESULTS
  Both continuous and weekly point prevalence smoking abstinence rates were significantly higher in the bupropion SR group compared with placebo. The continuous abstinence rate from weeks 4 to 7 was 46% in the bupropion SR group compared with 23% in the placebo group [odds ratio (OR) = 2.82; 95% confidence interval (CI) 1.89-4.28; P < 0.001). At month 12, the continuous abstinence rates were 21% for the bupropion SR group and 11% for the placebo group (OR = 2.19; 95% CI 1.29-3.86, P = 0.002). For most nicotine-withdrawal symptoms small changes were measured. Adverse events were higher for the bupropion SR group compared with placebo (insomnia 24% vs. 15%; dry mouth 13% vs. 5%).
  
  
  CONCLUSIONS
  Bupropion SR in combination with counselling increased the abstinence rate compared with placebo, and was well tolerated.
authors.affiliation: Department of Pulmonary Medicine, Gentofte University Hospital, Gentofte, Denmark. Philipt@dadlnet.dk
authors.forename: P
authors.initials: P
authors.lastname: Tønnesen
authors.forename: S
authors.initials: S
authors.lastname: Tonstad
authors.forename: A
authors.initials: A
authors.lastname: Hjalmarson
authors.forename: F
authors.initials: F
authors.lastname: Lebargy
authors.forename: P I
authors.initials: PI
authors.lastname: Van Spiegel
authors.forename: A
authors.initials: A
authors.lastname: Hider
authors.forename: R
authors.initials: R
authors.lastname: Sweet
authors.forename: J
authors.initials: J
authors.lastname: Townsend
mesh_terms: D000328:Adult; D016642:Bupropion / Q000009:adverse effects / Q000627:therapeutic use*; D003692:Delayed-Action Preparations / Q000627:therapeutic use; D018765:Dopamine Uptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009538:Nicotine / Q000378:metabolism; D016540:Smoking Cessation / Q000379:methods* / Q000523:psychology; D013375:Substance Withdrawal Syndrome / Q000523:psychology; D016896:Treatment Outcome; D015430:Weight Gain / Q000187:drug effects
chemical_list: D003692:Delayed-Action Preparations; D018765:Dopamine Uptake Inhibitors; D016642:Bupropion; D009538:Nicotine